1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18350
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiomou, E.en
dc.contributor.authorChalla, A.en
dc.contributor.authorPrintza, N.en
dc.contributor.authorGiapros, V.en
dc.contributor.authorPetropoulou, F.en
dc.contributor.authorMitsioni, A.en
dc.contributor.authorPapachristou, F.en
dc.contributor.authorStefanidis, C. J.en
dc.date.accessioned2015-11-24T18:52:04Z-
dc.date.available2015-11-24T18:52:04Z-
dc.identifier.issn1432-198X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18350-
dc.rightsDefault Licence-
dc.subjectAcid Phosphatase/blooden
dc.subjectAnalysis of Varianceen
dc.subjectBiological Markers/blooden
dc.subjectBone Remodelingen
dc.subjectCase-Control Studiesen
dc.subjectChilden
dc.subjectChild, Preschoolen
dc.subjectChronic Diseaseen
dc.subjectFemaleen
dc.subjectFibroblast Growth Factors/*blooden
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectIsoenzymes/blooden
dc.subjectKidney Diseases/*blood/diagnosis/physiopathologyen
dc.subjectMaleen
dc.subjectOsteoprotegerin/*blooden
dc.subjectParathyroid Hormone/blooden
dc.subjectPhosphates/blooden
dc.subjectRANK Ligand/*blooden
dc.subjectRegression Analysisen
dc.subjectSeverity of Illness Indexen
dc.titleSerum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney diseaseen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00467-011-1870-5-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21479768-
heal.identifier.secondaryhttp://www.springerlink.com/content/n630rn43h3464v6g/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractOsteoprotegerin (OPG), receptor activator of the nuclear factor kappaB ligand (RANKL) and fibroblast growth factor-23 (FGF-23) play a central role in renal osteodystrophy. We evaluated OPG/RANKL and FGF-23 levels in 51 children with chronic kidney disease (CKD) [n = 26 stage 3 or 4 (CKD3-4) and n = 25 stage 5 (CKD5)] and 61 controls. Any possible association with intact parathyroid hormone (iPTH) and bone turnover markers was also investigated. The OPG levels were lower in the CKD3-4 group (p < 0.001) and higher in the CKD5 group (p < 0.01) than in the controls, while RANKL levels did not differ. The FGF-23 levels were higher in both patient groups (p < 0.0001), while the levels of phosphate and iPTH were higher only in the CKD5 group (p < 0.0001). There were independent positive correlations between OPG and RANKL (beta = 0.297, p < 0.01) and FGF-23 (beta = 0.352, p < 0.05) and a negative correlation with the bone resorption marker TRAP5b (beta = -0.519, p < 0.001). OPG was positively correlated with iPTH (R = 0.391, p < 0.01). An independent positive correlation between FGF-23 and phosphate (beta = 0.368, p < 0.05) or iPTH (beta = 0.812, p < 0.0001) was noted. In conclusion, we found that higher OPG levels in patients with CKD stage 5 correlated with the levels of RANKL, FGF-23, iPTH, and TRAP5b. These findings may reflect a compensatory mechanism to the negative balance of bone turnover. High FGF-23 levels in early CKD stages may indicate the need for intervention to manage serum phosphate (Pi) levels.en
heal.journalNamePediatr Nephrolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Siomou-2011-Serum osteoprotegeri.pdf223.91 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons